文献速递炎症性肠病

Mirikizumab治疗克罗恩病的长期疗效与安全性:VIVID-2开放标签扩展研究

Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn's Disease: Results From the VIVID-2 Open-Label Extension Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-03-05

VIVID-2开放标签扩展研究纳入VIVID-1中接受mirikizumab治疗的465例患者(安全性人群)和430例疗效人群,评估治疗至104周的疗效与安全性。第2年64.7%发生治疗中出现的不良事件,7.7%发生严重不良事件。

要点

  • 第1年内镜应答者中81.8%–87.6%维持内镜应答至第104周。
  • 第1年内镜无应答者中30.9%–36.1%经再诱导后第104周达到内镜应答。

核心结论

  • Mirikizumab治疗克罗恩病至104周与持久改善相关,超过30%的1年内镜无应答者经再诱导后达到内镜应答,安全性特征与已知一致。

研究设计与样本

  • VIVID-2为开放标签扩展研究,纳入VIVID-1中随机接受mirikizumab并转入的患者,安全性人群465例,疗效人群430例。
  • 疗效人群包括VIVID-1第52周内镜应答者251例(300 mg皮下每4周)和内镜无应答者179例(第0、4、8周900 mg静脉再诱导后皮下给药)。
  • 缺失数据采用改良无应答填充(mNRI)和观察病例(OC)方法处理。

主要发现

  • 疗效人群第104周内镜应答率60.5%(mNRI)和67.1%(OC),内镜缓解率37.9%和41.7%,CDAI缓解率73.4%和80.9%。
  • 第52周内镜应答且达到指定终点者中,第104周维持内镜应答81.8%和87.6%,维持内镜缓解72.5%和78.6%,维持CDAI缓解86.9%和92.9%。
  • 第52周内镜应答但未达到指定终点者中,第104周获得内镜缓解33.3%和35.4%,获得CDAI缓解55.8%和60.8%。
  • 第52周内镜无应答者中,第104周达到内镜应答30.9%和36.1%。
  • 治疗第2年,64.7%患者发生治疗中出现的不良事件,7.7%发生严重不良事件。

临床怎么用

  • 对mirikizumab治疗1年的内镜无应答克罗恩病患者,可考虑静脉再诱导后继续治疗以争取内镜应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Mirikizumab, an anti-interleukin-23p19 monoclonal antibody, demonstrated efficacy and safety in patients with moderately to severely active Crohn's disease (CD) up to week (W)52 in VIVID-1. We present the first results from the VIVID-2 open-label extension study in patients who received mirikizumab for 2 years. METHODS: Of the patients randomized to mirikizumab in VIVID-1 who rolled over to VIVID-2, 465 were included in the safety population for this interim analysis, and 430 met the eligibility criteria for the efficacy population. Of those, 251 were endoscopic responders at W52 of VIVID-1 (300 mg subcutaneous dosing every 4 weeks) and 179 were endoscopic nonresponders at W52 of VIVID-1 (reinduced with 900 mg intravenously at W0, W4, and W8, followed by subcutaneous dosing). Missing data were handled using modified nonresponder imputation (mNRI) and observed case (OC) approaches. RESULTS: In the efficacy population, 60.5% (mNRI) and 67.1% (OC) achieved endoscopic response, 37.9% and 41.7% achieved endoscopic remission, and 73.4% and 80.9% achieved Crohn's Disease Activity Index (CDAI) remission at W104. Among W52 endoscopic responders who achieved the specified endpoint at W52, 81.8% and 87.6% maintained endoscopic response, 72.5% and 78.6% maintained endoscopic remission, and 86.9% and 92.9% maintained CDAI remission at W104. Among W52 endoscopic responders who did not achieve the specified endpoint at W52, 33.3% and 35.4% gained endoscopic remission, and 55.8% and 60.8% gained CDAI remission at W104. Among W52 endoscopic nonresponders, 30.9% and 36.1% achieved endoscopic response at W104. During the second year of mirikizumab treatment, 64.7% of patients experienced treatment-emergent adverse events (AEs), and 7.7% had serious AEs. CONCLUSIONS: Long-term treatment with mirikizumab for up to 104 weeks was associated with durable improvements in patients with CD. Over 30% of endoscopic nonresponders at 1 year achieved endoscopic response with mirikizumab reinduction. Safety was consistent with the known mirikizumab safety profile. CLINICALTRIALS: gov, Number: NCT04232553.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sands BE, Barnes EL, D'Haens G, et al. Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn's Disease: Results From the VIVID-2 Open-Label Extension Trial. Clin Gastroenterol Hepatol. 2026. PMID: 41794217. doi:10.1016/j.cgh.2026.01.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。